Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Acute promyelocytic leukemia (APL) is commonly complicated by a complex coagulopathy. Uncertainty remains as to which markers of bleeding risk are independent predictors. Drawing from 5 large clinical trials that included all-trans retinoic acid (ATRA) as part of induction, we assessed known determinants of bleeding at baseline and evaluated them as potential predictors of hemorrhagic death (HD) in the first 30 days of treatment. The studies included were ALLG APML3 (single arm of ATRA + idarubicin ± prednisone), ALLG APML4 (single arm of ATRA + idarubicin + arsenic trioxide + prednisone), CALGB C9710 (single arm of ATRA + cytarabine + daunorubicin), Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2491 (intergroup I0129, consisting of daunorubicin + cytarabine vs ATRA), and SWOG S0521 (single-arm induction of ATRA + cytarabine + daunorubicin). A total of 1009 patients were included in the original trials, of which 995 had sufficient data to be included in our multivariate analysis. In this final cohort, there were 37 HD cases during the first 30 days following induction, for an estimated cumulative incidence of 3.7% (95% confidence interval [CI], 2.6% to 5.0%). Using multivariate Cox proportional hazards regression, the hazard ratio of HD in the first 30 days was 2.17 (95% CI, 0.84-5.62) for an ECOG performance status of 3-4 vs 0-2 and 5.20 (95% CI, 2.70-10.02) for a white blood cell count of ≥20 000/μL vs <20 000/μL. In this large cohort of APL patients, high white blood cell count emerged as an independent predictor of early HD.

[1]  L. Campbell,et al.  Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. , 2015, The Lancet. Haematology.

[2]  J. Bergeron,et al.  Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan‐Canadian epidemiological study , 2014, British journal of haematology.

[3]  M. Tallman,et al.  Acute promyelocytic leukemia: what is the new standard of care? , 2014, Blood reviews.

[4]  H. Dombret,et al.  Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients , 2014, Leukemia.

[5]  R. Larson,et al.  Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy , 2014, British journal of haematology.

[6]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[7]  J. Reynolds,et al.  All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). , 2012, Blood.

[8]  L. Shih,et al.  Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia , 2012, European journal of haematology.

[9]  J. Reynolds,et al.  Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia , 2012, Haematologica.

[10]  J. Reynolds,et al.  All-trans-retinoic acid , idarubicin , and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia ( APML 4 ) , 2012 .

[11]  M. Schymura,et al.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. , 2011, Blood.

[12]  M. Baccarani,et al.  AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. , 2011, Blood.

[13]  M. Höglund,et al.  Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry , 2011, Leukemia.

[14]  Yunsuk Choi,et al.  Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. , 2011, Leukemia research.

[15]  R. Larson,et al.  Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. , 2010, Blood.

[16]  M. Sanz,et al.  Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. , 2010, Blood.

[17]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[18]  W. Hiddemann,et al.  High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG , 2009, Leukemia.

[19]  J. Esteve,et al.  Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. , 2008, Blood.

[20]  T. Naoe,et al.  Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome , 2007, European journal of haematology.

[21]  J. Rowe,et al.  Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. , 2005, Thrombosis research.

[22]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[23]  L. Pagano,et al.  Second malignancy after treatment of acute promyelocytic leukemia: experience of GIMEMA trials. Gruppo Italiano Malattie Ematologiche dell'Adulto. , 2002, Blood.

[24]  C. Bloomfield,et al.  All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .

[25]  F. Mandelli,et al.  Early haemorrhagic morbidity and mortality during remission induction with or without all‐trans retinoic acid in acute promyelocytic leukaemia , 2000, British journal of haematology.

[26]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[27]  O. Yamada,et al.  Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Barbui,et al.  Molecular Remission in PML/RARα-Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy , 1997 .

[29]  T. Barbui,et al.  Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. , 1997, Blood.

[30]  F. Mandelli,et al.  AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.

[31]  E. Freireich,et al.  Treatment of adult acute myeloblastic leukemia. , 1979, Haematology and blood transfusion.

[32]  A. Naidoo,et al.  Treatment of acute leukemia in children. , 1976, Canadian Medical Association journal.

[33]  G. Humphrey,et al.  Superiority of conventional intrathecal methotrexate therapy with maintenance over intensive intrathecal methotrexate therapy, unmaintained, or radiotherapy (2000‐2500 rads tumor dose) in treatment for meningeal leukemia , 1975, Cancer.

[34]  E. Frei,et al.  Comparative effects of the antitumor agents 5-(Dimethyltriazeno)-imidazole-4-carboxamide and 1,3-bis(2-chloroethyl)-1-nitrosourea on cell cycle of L1210 leukemia cells in vivo. , 1970, Cancer research.